期刊文献+

抗Tac单抗诱导治疗对肾移植受者外周血淋巴细胞CD分子表达的影响 被引量:1

Effect of anti-Tac monoclonal antibody on expression of CD molecules in peripheral lymphocytes of cadaveric kidney transplantation recipients
下载PDF
导出
摘要 目的:探讨首次尸肾移植受者使用抗Tac单抗诱导治疗后外周血淋巴细胞CD分子的动态变化及其临床意义.方法:对首次尸肾移植的患者,在三联免疫抑制方案(激素+骁悉+新山的明)基础上,给予两剂抗Tac单抗诱导治疗,其中舒莱组30例,赛呢哌组28例.以流式细胞仪检测术前,术后第1天、1周、2周、4周、6周及8周外周血淋巴细胞CD分子的表达.结果:移植受者外周血淋巴细胞CD分子变化明显,其中CD25在术后明显下降(P<0.05),并维持4~6周;CD40亦明显下降(P<0.05),术后2周时开始回升;CD86、CD28、CD80、CD95等均有下降,但各组间差异无统计学意义.舒莱组和赛呢哌组CD分子表达差异亦无统计学意义.结论:抗Tac单抗可以有效地封闭外周血活化淋巴细胞表面的CD25,抑制其增殖和分化;通过某种机制,抗Tac单抗可以降低外周血淋巴细胞CD40的表达,可能起到抑制B淋巴细胞活化的作用. Objective:To sequentially observe the CD molecule expression on the surface of peripheral lymphocyte in the primary cadaveric renal transplantation recipients treated with the induction therapy of anti-Tac monoclonal antibody, explore the molecular mechanism in relation to its immunological role.Methods:All the 58 patients were randomly divided into Simulect group (n=30) and Zenapax group (n=28), treated with the same triple-drug baseline immunosuppression (Cyclosporine microemulsion [Neoral], mycophenolate mofetil , and corticosteroid) and different induction therapy (2 doses of 20mg Simulect on day 0 and day 4, 2 doses of 50mg Zenapax on day 0 and day 14, respectively). Flow cytometer was used to count the number of lymphocytes expressing the different CD molecules. The times of assessment were day 0 (before transplantation), day 1, week 1, week 2, week 4, week 6, week 8 posttransplantation.Results:The expressions of CD molecules in the peripheral lymphocytes display dramatic fluctuation during the research. CD25 decreased significantly (P<(0.05)), and sustained until 6-8 weeks posttransplantation. CD40 also decreased obviously (P<(0.05)), with the lowest point at week 1 posttransplantation. The other molecules CD86, CD28, CD80, CD95 decreased with no significance (P>(0.05)), compared with pretransplantation. And the difference between the two groups can be neglected (P>(0.05)).Conclusions:Targeting at the CD25 molecule, the anti-Tac monoclonal antibody effectively inhibits the IL-2 pathway during the T cell proliferation and differentiation in the cadaveric renal transplantation. Through certain mechanism, anti-CD25 monoclonal antibody can decrease the expression of the CD40 on the surface of peripheral lymphocytes, maybe do some effect on the activation of B lymphocytes during the allograft transplantation.
出处 《临床泌尿外科杂志》 2005年第7期390-392,共3页 Journal of Clinical Urology
关键词 肾移植 淋巴细胞 流式细胞仪 <Keyword>Renal transplantation Lymphocyte Flow cytometer
  • 相关文献

参考文献14

  • 1Chow F Y, Polkinghorne K, Saunder A,et al. Historical controlled trial of OKT3 versus basiliximab induction therapy in simultaneous pancreas-renal transplantation. Nephrology (Carlton), 2003,8(4):212-216.
  • 2Zamora I, Berbel O, Simon J, et al. Anti-CD25 monoclonal antibody against polyclonal antibodies in pediatric renal transplantation. Nefrologia, 2002, 22(1):66-70.
  • 3Kuypers D R, Evenepoel P, Maes B, et al. The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients. Clin Transplant, 2003,17(3):234-241.
  • 4Weimar W, van Riemsdijk I C, Smak G P J, et al. Anti-CD25 prophylaxis allows steroid free kidney transplantation. Transplant Proc, 2001,33(7-8):3176-3177.
  • 5Cole E, Landsberg D, Russell D, et al. A pilot study of steroid-free immunosuppression in the prevention of acute rejection in renal allograft recipients. Transplantation, 2001,72(5):845-850.
  • 6Gonwa T A, Mai M L, Smith L B, et al. Immunosuppression for delayed or slow graft function in primary cadaveric renal transplantation: use of low dose tacrolimus therapy with post-operative administration of anti-CD25 monoclonal antibody. Clin Transplant, 2002,16(2):144-149.
  • 7Chang G J, Mahanty H D, Vincenti F, et al. A calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function. Clin Transplant, 2000,14(6):550-554.
  • 8Hong J C, Kahan B D. Use of anti-CD25 monoclonal antibody in combination with rapamycin to eliminate cyclosporine treatment during the induction phase of immunosuppression. Transplantation, 1999,68(5):701-704.
  • 9Wiland A M, Fink J C, Weir M R, et al. Should living-unrelated renal transplant recipients receive antibody induction? Results of a clinical experience trial. Transplantation, 2004,77(3):422-425.
  • 10Bingyi S, Ming C, Yeyong Q, et al. The effect of anti-CD25 monoclonal antibody (Simulect) to the lymphocytes in the peripheral blood of the recipients of kidney transplantation. Transplant Proc, 2003,35(1):243-245.

同被引文献6

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部